GeneCentric

GeneCentric Diagnostics is focused on developing and commercializing molecular diagnostic tests aimed at enhancing cancer treatment for oncologists and patients. The company has created two primary platform technologies: The Lung Subtype Platform (LSP), which stratifies lung cancer patients into specific subtypes to guide therapeutic selection, and the Hypoxia Signature, designed to identify patients likely to respond to anti-angiogenesis therapies. The LSP has been licensed for independent development by a partner and is accessible through its specialty testing service. GeneCentric's approach emphasizes collaboration to translate significant cancer research into diagnostics that are clinically applicable for pathologists and clinicians. Established in 2011, the company is headquartered in Durham, North Carolina.